HER2-Low Metastatic Breast Cancer (mBC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034

The HER2-Low Metastatic Breast Cancer (mBC) market is hugely contributed by chemotherapy, endocrine therapy and targeted therapy such as Trastuzumab deruxtecan (Enhertu). By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the HER2-Low Metastatic Breast Cancer therapeutics market. The sales of the emerging therapies for the treatment of HER2-Low Metastatic Breast Cancer in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2020-2034 study period.

"Experts believe that the treatment armamentarium for HER2-low metastatic breast cancer is rapidly evolving. Recent clinical trials have demonstrated the efficacy of CDK4/6 inhibitors in combination with endocrine therapy as a standard first-line treatment option. Additionally, the use of PI3K inhibitors and AKT inhibitors is being explored in clinical trials and may provide further treatment options in the near future."

The introduction of HER2-low metastatic breast cancer represents a significant shift in the understanding and treatment of breast cancer. Historically, breast cancers were categorized as either HER2-positive or HER2-negative based on the level of HER2 expression. However, more than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. IHC/ISH is the only standard technique currently applied to define HER2 expression. Recent evidence suggests that HER2-low breast cancer can be a targetable subgroup with potential therapeutic implications.

Mellalta's HER2-Low Metastatic Breast Cancer Report– Market Summary

Mellalta's HER2-Low Metastatic Breast Cancer Report – Epidemiology

The total incident cases of HER2-Low Metastatic Breast Cancer in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). As per estimates, the United States will present with the highest incidence of HER2-Low Metastatic Breast Cancer cases in 2034. Among the EU5, Germany had the highest HER2-Low Metastatic Breast Cancer cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States, Germany, and the UK.

According to SEER database estimates 287,850 new cases of female breast cancer will be diagnosed in 2022 in the U.S. Out of the newly diagnosed breast cancer patient, roughly 50-60% of patients is now diagnosed with HER2 Low metastatic Breast Cancer.

Mellalta's HER2-Low Metastatic Breast Cancer Report – Current Market Size & Forecast Trends

The HER2-Low Metastatic Breast Cancer therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034). The United States captured the highest market share as compared to the European 5 countries and Japan.

The current standard of care is limited to chemotherapy, endocrine and targeted therapy. In 2022, Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion is approved as the first targeted therapy for the treatment of patients with unresectable or metastatic HER2-low breast cancer in the United States and in 2023 in the European Union. This shift in treatment options has significant implications for the market. The changing treatment landscape has created new opportunities in the market for more companies to develop and commercialize the use of ADCs in HER2-low tumours. Additionally, the entrance of ADCs like Enhertu in the treatment paradigm of HER2-low breast cancer will also pave the way for diagnostic companies to develop the specific test for the identification of HER2-low breast cancer patient pool, which will be in turn increase the treated patient pool and will drive the market of HER2 low breast cancer significantly.

While the results of DESTINY-Breast04 study led to the breakthrough approval of Enhertu in the HER2 low breast cancer treatment space, it also changed the prescribing pattern among clinician's posing significant obstacles. These challenges include raising clinician awareness through education, updating practice guidelines, managing increasing treatment complexity, and addressing a lack of data surrounding the complex characteristics and temporal heterogeneity of HER2-low tumors.

In the 2024-2034 forecast period, there will be tremendous growth and shift in the therapeutic market with the launch of noble emerging therapies like Trastuzumab rezetecan (Jiangsu HengRui Medicine), DB-1303 (Duality Biologics), Disitamab vedotin (Yantai Rongchang Pharmaceutical), Sacituzumab Govitecan (Gilead Sciences), Datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo), MRG002 (Miracogen), and more. We expect a greater uptake of the new therapies which will result in better treatment outcomes for HER2-Low Metastatic Breast Cancer market space. The launch of these upcoming therapies will drive the highly competitive therapeutic market in the coming time.

Questions Answered:

• What is the size of clinically and commercially relevant drug-treatable HER2 low BC populations, and how will drug-treatment rates of HER2 change over time?
• What is the expected market impact of recent drug approval such as Enhertu in the treatment landscape of HER2-low metastatic BC?
• Potential challenges and opportunities in implementing targeted therapies for HER2-low breast cancer.
• What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?
• What key drivers and constraints will affect the HER2-low metastatic breast cancer therapy market over the forecast period?

Report Highlights:

• HER2-Low Metastatic Breast Cancer (mBC) – Current Market Trends
• HER2-Low Metastatic Breast Cancer (mBC) – Current & Forecasted Cases across the G7 Countries
• HER2-Low Metastatic Breast Cancer (mBC) – Market Opportunities and Sales Potential for Agents
• HER2-Low Metastatic Breast Cancer (mBC) – Patient-based Market Forecast to 2034
• HER2-Low Metastatic Breast Cancer (mBC) – Untapped Business Opportunities
• HER2-Low Metastatic Breast Cancer (mBC) – Product Positioning Vis-a-vis Competitors' Products
• HER2-Low Metastatic Breast Cancer (mBC) – KOLs Insight